Sab

1 known investors

SAB BIO develops disease-modifying therapeutics for Type 1 Diabetes that target the underlying autoimmune causes rather than managing symptoms. The company's lead candidate, SAB-142, aims to preserve insulin-producing beta cell function in patients with Type 1 Diabetes.